Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel α-Klotho Protein Therapy
Innovative Modified Soluble α-Klotho Protein Shows Promise for Treating the $16B Chronic Kidney Disease and Phosphate Metabolism Disorders Markets Boston, AM – October 14, 2025 – Anzor Pharmaceuticals is pleased to announce the issuance of U.S. Patent No. 12,227,777 B2 for a novel modified soluble α-Klotho protein with enhanced therapeutic properties. This breakthrough technology represents […]
Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia (XLH)
FDA Orphan Drug Designation offers Anzor key development incentives and seven years of market exclusivity, enhancing the therapy’s commercial potential. Boston, MA – July 24, 2025 – Anzor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead investigational therapy, a novel FGF23 peptide antagonist, for […]
Anzor Pharmaceuticals Selected to Present at the Prestigious BioLabs-NYU Investor & Innovator Exchange
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES Boston, MA – May 6, 2025 – Anzor Pharmaceuticals is honored to announce its selection as a presenting company at the 2025 BioLabs-NYU Investor & Innovator Exchange, taking place on May 6, 2025, in New York City. This high-profile event, now in its second year, […]
Anzor Pharmaceuticals to Present at Chronic Kidney Disease Conference
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES BOSTON, March 19, 2025 – Anzor Pharmaceuticals, a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced that Christopher P Adams, CEO will present at the 7th Annual Chronic Kidney Disease Conference in Boston Massachusetts on March 19, 2025. […]
Anzor Pharmaceuticals Licenses Key Fibroblast Growth Factor Technology From New York University
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES BOSTON, February 25, 2025 – Anzor Pharmaceuticals, a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced an exclusive worldwide license for FGF technology developed by Dr. Moosa Mohammadi, Ph.D., the company’s Chief Scientific Officer, who was previously a Professor […]
